BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30664602)

  • 1. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
    Maliha PG; Hudson M; Abikhzer G; Singerman J; Probst S
    Nucl Med Commun; 2019 Apr; 40(4):377-382. PubMed ID: 30664602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple values of
    Li Y; Zhou Y; Wang Q
    Clin Rheumatol; 2017 Oct; 36(10):2297-2305. PubMed ID: 28831580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis.
    Selva-O'Callaghan A; Grau JM; Gámez-Cenzano C; Vidaller-Palacín A; Martínez-Gómez X; Trallero-Araguás E; Andía-Navarro E; Vilardell-Tarrés M
    Am J Med; 2010 Jun; 123(6):558-62. PubMed ID: 20569766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of
    Motegi SI; Fujiwara C; Sekiguchi A; Hara K; Yamaguchi K; Maeno T; Higuchi T; Hirasawa H; Kodaira S; Tomonaga H; Tsushima Y; Ishikawa O
    J Dermatol; 2019 Mar; 46(3):213-218. PubMed ID: 30614031
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis.
    Owada T; Maezawa R; Kurasawa K; Okada H; Arai S; Fukuda T
    J Rheumatol; 2012 Aug; 39(8):1659-65. PubMed ID: 22753657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
    Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
    Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Garcia-Velloso MJ; Bastarrika G; de-Torres JP; Lozano MD; Sanchez-Salcedo P; Sancho L; Nuñez-Cordoba JM; Campo A; Alcaide AB; Torre W; Richter JA; Zulueta JJ
    Lung Cancer; 2016 Jul; 97():81-6. PubMed ID: 27237032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-Body
    Lebech AM; Gaardsting A; Loft A; Graff J; Markova E; Bertelsen AK; Madsen JL; Andersen KF; Benzon EV; Helms M; Mathiesen LR; David KP; Kronborg G; Kjaer A
    J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis.
    Rabkin Z; Israel O; Keidar Z
    J Nucl Med; 2010 Jul; 51(7):1015-20. PubMed ID: 20554733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Scan: Nuclear Medicine Imaging in Myositis.
    Selva-O'Callaghan A; Gil-Vila A; Simó-Perdigó M; Trallero-Araguás E; Alvarado-Cárdenas M; Pinal-Fernandez I
    Curr Rheumatol Rep; 2019 Nov; 21(11):64. PubMed ID: 31754890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis.
    Tanaka S; Ikeda K; Uchiyama K; Iwamoto T; Sanayama Y; Okubo A; Nakagomi D; Takahashi K; Yokota M; Suto A; Suzuki K; Nakajima H
    Rheumatology (Oxford); 2013 Jul; 52(7):1271-8. PubMed ID: 23479721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A follow-up analysis of positron emission tomography/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy.
    Feng Z; Wang S; Huang Y; Liang X; Shi W; Zhang B
    Oncotarget; 2016 Mar; 7(9):9645-51. PubMed ID: 27009881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
    Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
    Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.
    Chan HP; Liu WS; Liou WS; Hu C; Chiu YL; Peng NJ
    In Vivo; 2020; 34(1):469-478. PubMed ID: 31882515
    [No Abstract]   [Full Text] [Related]  

  • 19. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
    Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
    Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
    You JJ; Cline KJ; Gu CS; Pritchard KI; Dayes IS; Gulenchyn KY; Inculet RI; Dhesy-Thind SK; Freeman MA; Chan AM; Julian JA; Levine MN
    Br J Cancer; 2015 May; 112(11):1737-43. PubMed ID: 25942398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.